The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011; 66: 462-467.Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66:462-7.Navaratnam V, Fleming KM, West J, et al. The rising ...
What are the Key Data Covered in this Idiopathic Pulmonary Fibrosis Market Research Report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the market between 2023 and 2027 Precise estimation of the market size and its contribution ...
Pulmonary fibrosis is a progressive scarring disorder of the lung with dismal prognosis and no curative therapy. Clusterin, an extracellular chaperone and regulator of cell functions, is reduced in bronchoalveolar lavage fluid of patients with pulmonary fibrosis. However, its distribution and role in n...
working on epithelial cell involvement in smoking-induced lung diseases. Prof. Luppi’s primary research interests include interstitial lung diseases, particularly Idiopathic Pulmonary Fibrosis (IPF) and sarcoidosis, and he has been the Principal Investigator in several Phase II and III trials in IPF....
pulmonary conditions differed across the studies’ participants. Among the 110 total participants who were involved in the studies, the majority of them (38.2%) had cystic fibrosis. Moreover, 27.3% of the participants had COPD, and 19.1% of the total sample had asthma. The remaining ...
antagonist. When the lungs are injured, LPA is produced which leads to scarring (fibrosis) that reduces functioning of the lungs. This reduced function can lead to respiratory failure, which is fatal. Research has shown that blocking LPA1receptors may be beneficial in treating pulmonary fibrosis....
Non-small cell lung cancer (NSCLC) patients with idiopathic pulmonary fibrosis (IPF) show poor prognosis. Periostin is an extracellular matrix protein highly expressed in the lung tissues of IPF. This study aimed to investigate the possibility that perio
Pulmonary fibrosis (PF) is a major public health problem with limited therapeutic options. There is a clear need to identify novel mediators of PF to develop effective therapeutics. Here we show that an ER protein disulfide isomerase, thioredoxin domain
O. et al. A population study of endomyocardial fibrosis in a rural area of Mozambique. N. Engl. J. Med. 359, 43–49 (2008). Article CAS PubMed Google Scholar Weatherald, J. et al. Priorities for pulmonary hypertension research: a James Lind Alliance priority setting partnership. J. ...
matrix metalloproteinases(MMPs), and transforming growth factor-β have also been described to be involved inatrial remodelingleading to AF. In addition,preclinical studiessuggest that COPD is associated with heightened sympathetic activity, largerleft atriumand greaterfibrosisin thepulmonary veinsand left ...